Comparison 11. DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Photographic evaluation of mean change in acne at cycle 4	1	99	Mean Difference (IV, Fixed, 95% CI)	0.1 [‐0.10, 0.30]
2 Women with pustules or nodules at cycle 4	1	121	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.27 [0.62, 2.58]
3 Mean change in comedone count at cycle 4	1	121	Mean Difference (IV, Fixed, 95% CI)	3.70 [‐5.39, 12.79]
4 Mean change in papule count at cycle 4	1	121	Mean Difference (IV, Fixed, 95% CI)	‐0.60 [‐4.16, 2.96]
5 Mean change in pustule count at cycle 4	1	121	Mean Difference (IV, Fixed, 95% CI)	2.30 [‐0.15, 4.75]
6 Women with moderate acne at cycle 6	1	136	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.19 [0.61, 2.34]
7 Women with severe acne at cycle 6	1	136	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.00 [0.39, 10.21]
8 Mean comedone count at cycle 6	1	136	Mean Difference (IV, Fixed, 95% CI)	2.90 [0.05, 5.75]
9 Mean papule count at cycle 6	1	136	Mean Difference (IV, Fixed, 95% CI)	1.80 [‐0.40, 4.00]
10 Mean postule count at cycle 6	1	136	Mean Difference (IV, Fixed, 95% CI)	0.80 [‐0.35, 1.95]
11 Mean nodule count at cycle 6	1	136	Mean Difference (IV, Fixed, 95% CI)	0.0 [‐0.18, 0.18]
12 Discontinuation due to non‐acne adverse event	1	172	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.60 [0.45, 5.73]
13 Discontinuation due to worsening of acne	1	172	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.05 [0.06, 16.90]